23-Feb-2026
Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
Seeking Alpha News (Mon, 23-Feb 11:53 PM ET)
Seeking Alpha News (Mon, 23-Feb 9:25 PM ET)
Benzinga (Mon, 23-Feb 8:18 PM ET)
Hims & Hers beats on bottom line in Q4, but Q1 2026 revenue guidance disappoints
Seeking Alpha News (Mon, 23-Feb 4:54 PM ET)
HIMS Earnings: Hims & Hers Health Stock Down after Mixed Q4 Results
TipRanks (Mon, 23-Feb 4:16 PM ET)
Hims & Hers Health GAAP EPS of $0.08 beats by $0.03, revenue of $617.82M in-line
Seeking Alpha News (Mon, 23-Feb 4:07 PM ET)
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Business Wire (Mon, 23-Feb 4:05 PM ET)
P/E Ratio Insights for Hims & Hers Health
Benzinga (Mon, 23-Feb 1:00 PM ET)
Is HIMS Stock a Buy Ahead of Earnings? Options Traders Brace for 15% Price Swing
TipRanks (Mon, 23-Feb 10:47 AM ET)
Here are the major earnings after the close Monday
Seeking Alpha News (Mon, 23-Feb 10:00 AM ET)
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health Class A trades on the NYSE stock market under the symbol HIMS.
As of February 23, 2026, HIMS stock price declined to $15.51 with 28,199,903 million shares trading.
HIMS has a beta of 1.79, meaning it tends to be more sensitive to market movements. HIMS has a correlation of 0.11 to the broad based SPY ETF.
HIMS has a market cap of $3.53 billion. This is considered a Mid Cap stock.
Last quarter Hims & Hers Health Class A reported $599 million in Revenue and $.09 earnings per share. This beat revenue expectation by $18 million and missed earnings estimates by -$.01.
In the last 3 years, HIMS traded as high as $72.98 and as low as $5.65.
The top ETF exchange traded funds that HIMS belongs to (by Net Assets): VTI, VB, IJH, IWM, VBK.
HIMS has underperformed the market in the last year with a price return of -76.6% while the SPY ETF gained +13.0%. HIMS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.9% and -32.6%, respectively, while the SPY returned +4.9% and -1.2%, respectively.
HIMS support price is $14.59 and resistance is $16.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIMS shares will trade within this expected range on the day.